Official Title: “An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder”

Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term.

Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year.

Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.

Study Type: Interventional

Study Design: N/A

Study Primary Completion Date: December 2007

More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effective in the augmentation of SSRIs for treatment-resistant OCD.

Nevertheless, the AAPDs have been associated with common and serious adverse effects, such as body weight (BW) gain and metabolic dysregulation. Metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. Indeed, studies of some AAPD in SSRI-refractory OCD patients have similarly reported significant BW gain. AAPD-induced BW gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems.

Most work on AAPDs in treatment-refractory OCD has been conducted in the form of short-term efficacy studies. There have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where CBT is also provided, and where treatment is continued for a significant period of time. In the current effectiveness study, we sought to examine the response of SSRI-refractory patients to augmentation with AAPDs, comparing adverse events in such compared to a control group of SSRI responders.

Intervention(s) in this Clinical Trial

• Drug: atypical antipsychotic drug
  • For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
• Behavioral: exposure response prevention
  • After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: CBT
  • All subjects received cognitive-behavioral therapy (CBT) during the study period.
• Experimental: 1
  • Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
• Active Comparator: 2
  • Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.

Primary Measures

• Yale-Brown Obsessive-Compulsive Scale
  • Time Frame: 1 year
    Safety Issue?: No

Secondary Measures

• yale-Brown Obsessive-Compulsive Scale
  • Time Frame: 1 year
    Safety Issue?: No
• BMI, TG, T-CHO, FBS
  • Time Frame: 1 year
    Safety Issue?: Yes

Inclusion Criteria:

• Male or female, 18 years of age or over
• Patients were diagnosed as having obsessive-compulsive disorder by the Structured
• Clinical Interview for DSM-IV Patient version (SCID-P)
• They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
• Each subject gave written informed consent to take part after receiving a complete description of this study.
• All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.

Exclusion Criteria:

• Current clinically significant medical conditions such as diabetes

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 50 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Osaka City University

Information obtained from ClinicalTrials.gov on February 04, 2010

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00854919

Study ID Number: 18591305

ClinicalTrials.gov Identifier: NCT00854919

Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology